NEW YORK – Single-cell proteomics firm IsoPlexis announced Tuesday an exclusive agreement with Neoline Technology to distribute IsoPlexis' products in China.
The partnership will provide Chinese customers access to the Brandford, Connecticut-based company's IsoLight platform, which enables multiplexed immunoassays at the single-cell level.
"We are very excited to partner with Neoline Technology, a leading distributor of life science systems and technology in China," IsoPlexis CEO Sean MacKay said in a statement. "Our single-cell proteomics platform provides a wide range of applications across therapy and vaccine development, as well as biomarker discovery, and we look forward to our systems generating impactful data at leading global pharmaceutical companies, research laboratories, and academic institutions."
"With our cooperation with IsoPlexis, we expect the addition of their novel technology to provide Chinese clients with a powerful and highly efficient tool in terms of single-cell protein analysis," said Neoline CEO Hu Jun.